Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pumitamig + paclitaxel
- Development stage
- Unknown
- Lead developer
- BioNTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Pumitamig + paclitaxel** is a combination therapy comprising pumitamig (also known as BNT327 or PM8002) and paclitaxel. Pumitamig is a novel bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), designed to simultaneously modulate immune checkpoint inhibition and angiogenesis. Paclitaxel is a well-established microtubule-stabilizing chemotherapeutic agent that disrupts mitosis, leading to cell death. This combination is under investigation, primarily for the treatment of triple-negative breast cancer (TNBC), where it is being evaluated for its potential to improve antitumor activity by integrating immunotherapy with cytotoxic chemotherapy. BioNTech SE is currently the primary developer and sponsor of this combination; Biotheus has also been referenced in China-based trials.
- Brand names
- AbraxaneTaxol
- Other names
- pumitamig + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on pumitamig + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pumitamig + paclitaxel.